Cancer continues to be one of the main public health problems since it is the second cause of death in the world. At present, chemotherapy is considered conventional therapy for several illnesses of this group; however, it still has certain limitations, such as the low selectivity of action towards the cancer cells and the low susceptibility, which they develop to drugs for clinical use. Due to the aforementioned drawbacks, we are still looking for compounds that can act through different mechanisms of action and at different levels of carcinogenic processes. Currently, there are reports that the modification of the redox status of cancer cells can lead them to death. From this premise we have looked for molecules that affect the functioning of Xanthine oxidase (XO) in order to modify the cellular redox balance, taking advantage of the fact that this enzyme is over-expressed and that it is one of the sources of reactive oxygen species (ROS) in malignant cells. It has been observed that some derivatives of N- (2,4-diaminoquinazolin-6-yl) carboxamides show inhibitory activity against XO. One of them, the so-called <b>MLB13</b>, stood out for its inhibitory action and antioxidant potential; however, it presented problems of low aqueous solubility, which limited its evaluation in cultures of different malignant cell lines. For this reason, the objective of this work is to carry out the synthesis of <b>MLB13</b> by means of an alternate synthesis route to subsequently be able to synthesize some of its prodrugs of amino acid esters and thus being able to increase its aqueous solubility and antioxidant potential.

Synthesis of prodrugs from a quinazoline derivative to optimize its behavior against cancer cells

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.